Work Here?
Ottobock
Work Here?
Provider of prosthetics, orthotics, wheelchairs, exoskeletons
Ottobock
Work Here?
Provider of prosthetics, orthotics, wheelchairs, exoskeletons
Overview
Ottobock is a global producer of orthopedic technology, focusing on prosthetics, orthotics, wheelchairs, and exoskeletons. Its products range from basic devices to advanced, microprocessor-controlled prosthetics and ergonomic exoskeletons that help people move more easily and stay independent. These devices work by using sensors, motors, and smart controls to adapt to a user’s movement, pace, and terrain, providing ankle and knee assistance or full upper- and lower-limb support. compared with others, Ottobock stands out as a family-owned company with a long history, a broad international footprint in about 60 countries, a large workforce, and a strong commitment to social responsibility, including a long-running partnership with the Paralympic Games. Its core goal is to improve mobility and quality of life for people with disabilities by delivering reliable, high-quality mobility solutions.
About Ottobock
Industries
Robotics & Automation
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Duderstadt, Germany
Founded
1919
Simplify's Take
What believers are saying
- Ottobock's October 2025 IPO priced at €66, signaling strong investor demand.
- The company generated €237 million free cash flow against €91.8 million statutory profit.
- RESTORE's first-in-human procedure in Vienna creates a clinical milestone for premium differentiation.
What critics are saying
- Näder Holding still controls over 81%, limiting float and amplifying volatility.
- Ottobock funded Blue Arbor, helping a potential future competitor define neural-control standards.
- If reimbursement shifts toward implanted interfaces, Ottobock's hardware margins compress quickly.
What makes Ottobock unique
- Founded in 1919, Ottobock leads prosthetics, orthotics, wheelchairs, and exoskeletons.
- Its full treatment-cycle model spans products, fittings, rehabilitation, and long-term patient support.
- The Blue Arbor partnership gives Ottobock early access to implanted neuromuscular control technology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.1B
Above
Industry Average
Funded Over
3 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Company Match
100% company-paid short & long-term disability
Company News
Blue Arbor Technologies has secured a $5 million investment from Ottobock, the global prosthetics leader, to advance its RESTORE Neuromuscular Interface System. Ottobock will lead Blue Arbor's Series A financing and hold a board seat. The FDA breakthrough-designated RESTORE System provides a fully implanted neuromuscular interface connecting advanced prostheses directly to patients' residual muscles and peripheral nerves. It enables independent, simultaneous control of fingers, wrist and elbow, with trials demonstrating stable signal capture for over five years. In December 2025, surgeons at the Medical University of Vienna completed the first-in-human RESTORE procedure. Within days, the patient demonstrated functional use with an Ottobock prosthetic. Founded by Drs Paul Cederna, Theodore Kung and Alex Vaskov, Blue Arbor has been awarded over $60 million in research grants and published more than 200 peer-reviewed papers.
Blue Arbor Technologies announces $5 million investment by Ottobock to advance RESTORE™ System, designed to enable intuitive prosthetic control
Onward has completed its capital round, securing €50.85 million from a group of major investors.
Ottobock SE & Co. KGaA shares have been stabilizing since their IPO on October 14, with trading starting at €66.00. The lowest price reached was €64.50 on October 17. Stabilization measures, managed by Goldman Sachs Bank Europe SE, have been conducted daily across multiple trading venues, including XETRA and the Frankfurt Stock Exchange. The base offering included 10,640,151 shares. The shares are trading under ISIN DE000BCK2223.
Ottobock SE & Co. shares rose in the prosthetics firm’s debut trading session in Frankfurt on Thursday, after the biggest initial public offering in Germany in more than a year.
Ottobock is Hiring for 26 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Ottobock
Industries
Robotics & Automation
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Duderstadt, Germany
Founded
1919
Ottobock is Hiring for 26 Jobs on Simplify!
Find jobs on Simplify and start your career today